Introduction
T h e concept of inhibition of protein expression by antisense oligonucleotides has emerged over the last few years as an important and potentially very powerful alternative to traditional drug design strategies [ 1-51. First advocated by Zamecnik and Stevenson in 1978 [6,7] , this approach rests on the basic idea that the binding of a relatively small synthetic oligonucleotide ('antisense' oligonucleotide) to a complementary base sequence on a target mRNA can lead to very specific suppression of the expression of the corresponding protein as the result of inhibition of translation. Such an inhibitory effect on RNA translation can occur through a variety of mechanisms (which will be defined in more detail below), and, in its functional consequences, is equivalent to the inhibition of protein function, e.g. by small molecule enzyme inhibitors or receptor antagonists. However, by exploiting the very specific rules that Nature has developed for the mutual recognition of complementary nucleic acids, an antisense strategy potentially offers a degree of specificity in its mechanism of action that is not generally attainable with small molecule protein inhibitors.
For the basic principle outlined above to be elevated to the level of a sustainable drug-design and drug-development strategy, an antisense oligonucleotide has to fulfil a number of requirements, failure to meet any one of which is almost bound to abolish any therapeutic utility [ 1-51.
(i) T h e oligonucleotide has to exhibit a reasonable metabolic stability in a physiological environment. (ii) It has to bind to its target RNA with high affinity and specificity. (iii) It must be taken up by the target cells and tissues at a reasonable rate and to a reasonable extent. (iv) It has to show appropriate pharmacokinetic and pharmacodynamic behaviour.
Abbreviations used: PS-ODN, phosphorothioatc oligodeoxynucleotide; P I C , protein kinase C.
Natural oligonucleotides (i.e. short pieces of single-stranded DNA based on a phosphodiester backbone) are very rapidly degraded under physiological conditions by the action of singlestranded nucleases (primarily 3'-exoiiucleases) and therefore cannot act as potent antisense inhibitors of gene expression in 7 3 i . z~) or even in cell culture [ 1-5,8]. As a consequence extensive efforts have been made over the past few years to design and synthesize chemically modified oligonucleotides or oligonucleotide analogues that would exhibit improved nuclease resistance, but retain the ability to bind to complementary RNA with high affinity and specificity [9-121.
With regard to biological applications, oligonucleotides based on a nuclease-resistant pliosphorothioate backbone (with one of the non-bridging oxygen atoms of the internucleoside phosphate group being replaced by a sulphur atom) ( Figure 1A ) represent the most extensively investigated class of modified oligonucleotides to date [ 1-5,131. I'hosphorothioate oligonucleotides (PS-ODNs) in several cases have proven to be very potent and also selective inhibitors of protein expression in 7 Y / i n [14] [15] [16] [17] as well as in 7 i 7 v [18] [19] [20] [21] [22] , two of the most prominent examples being signal-transduction itihibitors CGP64128A (ISIS 3521) [17, 20, 21] and CGP69846A (ISIS 5132) [22] (Figure 1B) .
Both of these compounds are 20-mer PS-ODNs which are directed against human protein kinase C (PKC)-y and c-Raf kiriase RNA respectively, and both have been shown to be very potent inhibitors of turnour growth in experimental animals. Clinical studies with CGP64128A as well as CGP69846A are currently in progress.
Despite . It thus appears that the design of nuclease-resistant modified oligonucleotides with improved KNAbinding affinity and/or reduced sulphur content, i.e. reduced potential for unspecific protein binding, should lead to more potent and perhaps less toxic second-generation antisense molecules
In this paper we report on the design and biological activity of such second-generation antisense oligonucleotides, with special emphasis on the design of improved analogues of signal-transduction inhibitors CGP64128A and CGP69846A.
1241.

Second-generation antisense oligonucleotides and RNase H window strategy
There are two principal mechanisms by which antisense oligonucleotides can elicit a biological response at the level of protein translation, one of which involves simple steric blockage of a variety of processes involved in the sequence of events This is most dramatically illustrated by the fact that a fully 2'-methoxy-substituted version of CGP64128A almost completely lacks the ability to inhibit PKC-(x expression, although its binding constant for the complementary RNA sequence it2 p i t m is %400-fold higher than that of CGP64128A [17] .
One possible way to overcome the limitations imposed by the sensitivity of RNase H to structural alterations in the DNA strand of DNA/ RNA heteroduplexes is the use of only partially modified chimaeric oligonucleotides, a concept originally introduced by Inoue and co-workers for 2'-O-methyl-modified oligoribonucleotides [34] and later also extended to other non-RNase H-activating modifications by others [31, . In essence, this strategy involves the introduction of chemical modifications only in the terminal regions of an antisense oligonucleotide ('wings'), while the central part of the sequence ('gap'; 'RNase H window') retains a (nuclease-resistant) 2'-deoxyphosphorothioate structure (Figure 2 ). If chosen appropriately, i.e. for 6-8 bases in length, the presence of an RNase H window allows KNase H-induced cleavage of bound target RNA, while any beneficial properties associated with a particular modification can still be conferred on the oligonucleotide by modification of the flanking regions. Most importantly, for modifications providing a high enough degree of nuclease resistance, this approach allows the design of antisense oligonucleotides with a reduced number of phosphorothioate linkages and thus reduced potential for phosphorothioaterelated unspecific side effects.
2'-O-Methoxyethyl-substituted ribonucleosides as building blocks for antisense oligonucleotides
Oligonucleotides incorporating certain 2'-0-alkyl-substituted ribonucleotide units have been shown in the past to exhibit improved RNAbinding affinities (as compared with the corresponding unmodified parent oligodeoxyribonucleotides) [ 16,30,38-401; in addition, such substituents significantly reduce the susceptibility of the neighbouring phosphodiester group to nucleolytic cleavage [30,3 1,40-421. However, the degree of nuclease resistance conferred by a simple Z'-O-methyl substituent does not completely suffice for the corresponding phosphodiester-based oligonucleotides to be useful for antisense applications (see below). Larger alkyl groups than methyl lead to further improved nuclease resistance, but also exert less beneficial effects on RNA binding, to the extent that the RNA-binding affinity of a fully 2'-O-pentylmodified oligoribonucleotide in general does not exceed that of the parent oligodeoxyribonucleotide (Table 1) . It is this inverse relationship between nuclease stability and RNA-binding affinity which severely hampers the application of ribonucleosides bearing simple Z'-O-alkyl substituents as building blocks for antisense oligonucleotides.
In contrast with simple 2'-O-alkyl groups, we have recently demonstrated that Z'-O-oligoethylene glycol substituents combine favourable effects on RNA-binding affinity with largely increased nuclease resistance [43] . Oligonucleo tides incorporating Z'-O-methoxyethyl (2'-OCH2-CH20CH3)-substituted ribonucleotides exhibit similar or even slightly higher RNA-binding affinity than the corresponding 2'-0-methyl-substituted analogues (Table l) , but at the same time are at least one order of magnitude more resistant to nucleolytic degradation [43] . It seems [43] . These features make 2'-0-oligoethylene glycol substituents very attractive candidates for incorporation into biologically active antisense oligonucleotides, with our initial focus being directed towards a comprehensive evaluation of the properties of the Z'-O-methoxyethyl group as the simplest representative of this family of 2'-0-substituents.
Various chimaeric analogues of CGP69846A have therefore been prepared and assessed for their ability to induce down-regulation of c-Raf kinase mRNA in T24 (bladder carcinoma) cells (with t, c, g, 2 signifying 2'-0-methoxyethyl-substituted ribonucleotides, p indicating a phosphodiester group, and s indicating a phosphorothioate group):
Not unexpectedly, CGP72809A with a four-base 2'-deoxy gap at 100 nM concentration does not lead to any observable reduction in c-Raf kinase mRNA levels 24 h after treatment, indicating that 2'-0-methoxyethyl-substituted ribonucleotides as such do not support RNase H activity. CGP73231A with a six-base gap at the same concentration reduces RNA levels to 60% of control, whereas CGP69845A (eight-base gap) is significantly more potent and reduces c-Raf kinase mRNA to only 20% of control levels after 24 h. On the basis of these data, only CGP69845A has been further characterized in dose-response experiments and its activity has been compared with that of CGP69846A itself and other 2'-substituted analogues.
As illustrated in Table 2 , CGP69845A exhibits significantly higher RNA-binding affinity than CGP69846A and it inhibits c-Raf kinase mRNA expression in T24 cells with an IC5,, of ~2 0 nM. In spite of a 50% reduction in thioate content, CGP69845A is thus a 4-fold more potent inhibitor of c-Raf kinase mRNA expression than CGP69846A. In contrast, the corresponding 2'-O-methyl-substituted analogue of CGP69846A (Table 2 ; R = OCH3, x = PO) does not show any detectable activity at 500 nM concentration, thus corroborating the far superior nuclease resistance of 2'-O-methoxyethyl-modified phosphodiester-based oligonucleotides. In line with these arguments, similar activities are observed for the 2'-0-methyl-and 2'-0-methoxyethyl-modified chimaeric analogues of CGP69846A that are based on a full phosphorothioate backbone (Table 2 ; x = PS), while the activity of the corresponding 2'-O-propyl-substituted analogue (Table 2 ; R = OC3H7, x = PS) is comparable with that of CGP69846A. However, even in combination with a nuclease-resistant phosphorothioate backbone the introduction of 2'-O-propyl substituents into CGP69846A does not lead to the same level of activity as the 2'-0-methoqethyl group (in combination either with a phosphodiester or a phosphorothioate backbone). In addition to the data shown in Table 2 Down-regulation of c-Raf rnRNA by 2'-substituted chirnaeric analogues of CGP69846A Table 2 , the very profound effect of a 2'-0-CGP69845A are not significantly elevated over methoxyethyl group on nuclease resistance and those observed at 24 h (results not shown). biological activity of antisense oligonucleotides is
The differences in nuclease stability also attested to by the fact that c-Raf mRNA between CGP69845A and a 2'-O-methyl-snbstilevels in T24 cells even 60 h after treatment with tuted chimaeric analogue of CGP69846.A have Table 3 Down-regulation of PKC-z rnRNA by 2'-substituted chirnaeric analogues of CGP64 I28A
Cells were treated with oligonucleotides in the presence of 10 @ml lipofectin for 4 h and 37 C After treatment, medium was removed and replaced with normal cell culture medium PKC x mRNA was determined by Northern-blot analysis 24 h after initiation of oligonucleo tide treatment by means of a random-primed "P-labelled full-length bovine cDNA probe n d , not determined PO, phosphodiester, PS, phosphorothioate also been independently confirmed with snake venom phosphodiesterase, which degrades the latter about six times more rapidly than CGP69846A, whereas CGP69845A is even slightly more stable than CGP69486A ( = 1.06-fold).
Similar effects on antisense activity in cell culture (A549 cells) were observed upon modification of PKC-r inhibitor CGP64128A with different types of 2'-0-substituents.
As in the case of CGP69846Al incorporation of 2'-0-methoxyethyl-modified building blocks (CGP75182A) allows a more than 50% reduction of the thioate content of the oligonucleotide with a concomitant 6-fold increase in potency (ICo, ~2 5 nM compared with 150nM for CGP64128A) ( Table 3 ) . No significant difference in inhibitory potency is observed between CGP75182A and a full thioate version of this compound.
As a result of the very promising in eitvu data for CGP69845A and CGP7518W, both of these oligonucleotides have also been tested for their ability to inhibit tumour growth in 7 i 7 v . For this purpose a variety of different tumour types were subcutaneously transplanted on to female Balb/c nude mice, which were then treated with different doses of CGP69845A and CGP75182A. It should be noted that in contrast with the situation in cellular experiments, where oligonucleotides are administered in the presence of cationic lipids in order to enhance cellular uptake [44] , oligonucleotide treatment in 7 i 7~1 (by either intravenous or subcutaneous injection) is performed with a simple saline solution of these compounds in the absence of any cellular uptake promoters.
ils shown in Figure 3 both CGP69845A and CGP75 182A are very potent inhibitors of tumour growth in experimental animal models and even surpass the antitunlour activity of the respective parent phosphorothioates CGP69846A and CGP64128A. In both cases very strong retardation of tumour growth is observed at doses as low as 0.06 mg/kg. 'The effect of the modification appears to be more pronounced in the case of CGP75182A, which at a daily dose of 0.06 mg/ kg exhibits virtually the same activity as CGP64128A at 6mg/kg per day. However, it should be noted that the data shown in Figures  3@1) and 3 ( H ) cannot be compared on a one to one basis, as the two oligonucleotides were investigated in different types of tumours (A549 for CGP69845A and colo 205 for CGP75182A).
In order to gain a better understanding of the various parameters that determine the biological activity of 2'-O-methoxyethyl-modified oligonucleotides in v i 7 1 0 , we have also conducted pharmacokinetic studies on CGP69845A in tumour-bearing mice. In comparison with the parent phosphorothioate CGP69846A, which shows pharmacokinetic properties more or less typical of other PS-ODNs (rapid biphasic clearance from the blood with the kidney and liver as high-affinity tissues, but also readily detectable accumulation in skin, bone, heart, lung and tumour) [45, 46] CGP69845A is cleared from the body much more rapidly, which is reflected in significantly higher concentrations of oligonucleotide in urine and kidney. At the same time the affinity for liver and spleen is clearly reduced and concentrations comparable with those of 
